logo
Anna Wintour is hiring at Vogue. Here's how to thrive when your boss used to have your job.

Anna Wintour is hiring at Vogue. Here's how to thrive when your boss used to have your job.

Business Insider3 hours ago

Whomever replaces Anna Wintour in running day-to-day operations at American Vogue will have some enormous stilettos to fill.
That's partly because Wintour, who's 75, has been at the job for nearly four decades and is a legend in the business. It's also because whoever comes next will report to her.
Wintour, who became Vogue's editor in chief in 1988, is giving up that role. However, she'll remain global editorial director at the magazine and chief content officer for its parent company, Condé Nast, the company said Thursday.
Taking on a senior role, similar to the one Wintour vacated at Vogue, is often challenging, especially when the predecessor remains on hand, leadership experts told Business Insider.
Incoming leaders are wise to signal that they want to make changes without abandoning what makes an organization work, said Kevin Groves, a professor of management at Pepperdine's Graziadio Business School.
"We're preserving what's most important to us, while recognizing our environment has changed," he said.
Here are three pieces of advice on taking over after a leader who looms large — and who might still be down the hall.
Don't be impatient
Stepping into this position successfully starts with indicating sincere interest in the role and prioritizing what's best for the organization, Nancy Ho, an executive coach based in Singapore, told BI.
"You cannot be impatient and rush into it. It should not be seen like you're power-hungry or claiming a role prematurely," Ho said.
Instead, she said, new leaders need to focus on understanding a company's culture and how they can position themselves as an asset to the organization.
James Reed, CEO of the UK-based recruitment company Reed, said there is no harm in declaring to your boss that you are ambitious and aim to lead an organization, "even if you avoid explicitly saying you're after their job."
"Ask what you need to learn and what more you can contribute to support them," Reed said. "Then they will be aware of your ambition but appreciate that you are seeking to help and learn from them rather than undermine them."
Don't rock the boat too early
Ho said it's important not to make drastic changes too soon upon getting the job. Ho recommended that the first step is acknowledging the good work done before them. Then, they should gain the team's trust by carefully working with them and making small, gradual changes to improve the organization's effectiveness.
"When there's a certain buy-in, and people are more comfortable with a different leader, then you introduce changes," she said.
Sabina Nawaz, a US-based CEO coach, said new leaders should not make changes for at least the first three months because the first thing to do after receiving the title is "to be curious."
"Go on a listening tour, excavate the reasons behind decisions or actions, try to make sense of things from the perspective of others: given that they're smart and well-meaning, what did they have in mind when they acted this way," Nawaz said.
Christian Tröster, a professor of leadership and organizational behavior at Germany's Kühne Logistics University, told BI that new leaders can demonstrate they're becoming part of the organization by being careful not to suggest that everything should change.
"Because then you're showing that you are not like them, that you cannot be trusted," Tröster said. "Then you don't have the commitment of your employees to actually go with you."
Tröster said that when an incoming leader would have to report to the person who held the post in the past, it's important to have a conversation about expectations.
He said that while org charts are often clear, layers are often not always evident, including what relationships people have and who they tend to go to for advice.
"I would try to make that visible," Tröster said. That way, he said, workers know who they're expected to go to and leaders and employees can agree to the arrangement.
Don't be afraid to be different
For those taking over a new role while their predecessor is still around — especially someone as "established and admired" as Anna Wintour, it's important to take advantage of your access to them, Amanda Augustine, a career coach at resume.io, told BI via email.
"Start the job as a sponge, learning what you can from your predecessor and other colleagues," she said, adding that it's important not to stay in information-gathering mode forever.
Jochen Menges, a professor of leadership at the University of Zurich and the University of Cambridge, told BI that new leaders should "be different" and avoid trying to replicate the exact leadership style or strategy of the person they're replacing.
"If they're too close, then they'll seem to be a copy, and then they can never live up," he said. When new bosses are different in some ways, Menges said, they can be "a leader in their own right."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

[UPDATE] University of Bridgeport and Goodwin University Revolutionize Regenerative Medicine Training Program Forming Strategic Alliance with Globally Recognized TulsiHub Institute
[UPDATE] University of Bridgeport and Goodwin University Revolutionize Regenerative Medicine Training Program Forming Strategic Alliance with Globally Recognized TulsiHub Institute

Business Upturn

time30 minutes ago

  • Business Upturn

[UPDATE] University of Bridgeport and Goodwin University Revolutionize Regenerative Medicine Training Program Forming Strategic Alliance with Globally Recognized TulsiHub Institute

BRIDGEPORT, CT, June 27, 2025 (GLOBE NEWSWIRE) — The two leading academic institutions have joined forces with TulsiHub Institute, the premier provider of advanced CE certified regenerative medicine certification programs, to transform medical education standards across regenerative medicine and cellular therapy disciplines. This innovative alliance positions both universities as pioneers in cutting-edge healthcare training while establishing new industry standards for professional medical certifications and continuing medical education in the rapidly expanding regenerative healthcare sector. Universities Pioneer Advanced Regenerative Medicine Education Partnership With the global regenerative medicine market expected to expand from $60 billion in 2023 to over $375 billion by 2031, this exponential growth creates significant demand for qualified practitioners capable of delivering advanced regenerative treatments including stem cell therapy, tissue engineering, and cellular therapy applications. The collaboration establishes both institutions as pioneers in advanced healthcare education, directly responding to the urgent need for comprehensive regenerative medicine training in the United States. This partnership addresses critical gaps in medical education across multiple regenerative medicine disciplines, including stem cell therapy, gene therapy, tissue engineering, cellular therapy, PRP (Platelet Rich Plasma) therapy, EBOO Therapy, Exosome therapy, Prolotherapy, and Shockwave therapy. 'It's a call to shape the very future of medicine,' remarked President Mark E. Scheinberg. 'We are excited to help forge a new generation of healthcare professionals who will redefine what's possible in patient care.' First-of-Its-Kind CE Certified Regenerative Medicine Training Program in the U.S. Through this strategic alliance, students gain access to the first intensive and comprehensive CE certified regenerative medicine training program of this caliber in the United States. The program features 12 specialized medical courses delivered through a unique 8-to-12-week intensive training methodology that combines theoretical medical knowledge with extensive practical training, ensuring certified healthcare professionals achieve clinical competency in cutting-edge regenerative medicine techniques. The evidence-based curriculum provides healthcare professionals with comprehensive on-site instruction under expert medical supervision with extensive hands-on experience. This approach ensures graduates possess both theoretical understanding and practical expertise in regenerative medicine applications, responding to urgent market demand from healthcare professionals seeking advanced training in regenerative therapies without geographic barriers. Students benefit from generous scholarships provided by TulsiHub Institute, along with access to seed funding opportunities of US$100,000 for establishing their own regenerative medicine clinics, and favorable lifetime discounts on medical consumables to support the ongoing success of their practices. This comprehensive support system addresses the practical implementation challenges newly certified practitioners face, providing essential financial resources to successfully transition from training to clinical application. 'This strategic collaboration establishes our institution as a leader in advanced healthcare education while reinforcing our dedication to equipping students and medical professionals with innovative training programs that address evolving industry requirements,' said University of Bridgeport President Danielle Wilken, Ed.D. Global Leader in Regenerative Medicine Certification TulsiHub Institute consortium maintains an exceptional 98% certification success rate while delivering internationally recognized credentials to medical professionals across 25 countries worldwide. As the gold standard in CE certified regenerative medicine certification, they have successfully certified over 500 healthcare professionals through comprehensive training programs. 'This partnership marks the first and only intensive and comprehensive CE certified regenerative medicine training program of this caliber available in the United States. We are responding to urgent market demand from healthcare professionals seeking advanced training in regenerative therapies without geographic barriers,' said Dr. Natasha Macleay, CEO of TulsiHub Institute. This institution also offers comprehensive certification programs equipping students with the latest advancements in longevity, preventive care, anti-aging protocols, in specialized areas like Dermatology, Orthopedics, Oncology Care, and Dentistry supported by a world-class faculty, advanced research facilities, and a dynamic community for collaboration. Academic Excellence and Leadership To ensure the highest standard in academic oversight, the program involves key University of Bridgeport leadership, including: Elena Cahill, JD, VP of Innovation, Strategy, and Advancement. Dr. Michael Ciolfi, Dean of the College of Health and Sciences; and Dr. James Lehman, Director of Health Sciences Postgraduate Education. The combined expertise of these individuals along with Raghav Goyal Co CEO of TulsiHub ensures the program maintains rigorous academic standards while addressing current industry requirements. Program Eligibility The program welcomes medical students, practicing physicians, nurses, chiropractors, and other healthcare professionals seeking specialized and CE certified regenerative medicine expertise. Eligibility encompasses MD, DO, DC, ND, DPM, PA, APRN degree holders, as well as RN, LPN, NP, CRNA, CNS, and CNM professionals. Visit to learn more about the courses and our partnership with the University of Bridgeport and Goodwin University. For media inquiries, please contact: Email: [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Is META Stock a Buy, Sell, or Hold as Meta Platforms Launches New v-JEPA 2 AI Model?
Is META Stock a Buy, Sell, or Hold as Meta Platforms Launches New v-JEPA 2 AI Model?

Yahoo

time34 minutes ago

  • Yahoo

Is META Stock a Buy, Sell, or Hold as Meta Platforms Launches New v-JEPA 2 AI Model?

As the artificial intelligence (AI) race accelerates toward advanced machine intelligence (AMI), tech giants are pushing boundaries to create agents that can reason more like humans. A key piece of this puzzle is physical reasoning, essential for AI systems to navigate and act within the real world. Meta Platforms (META) has stepped into this frontier with the launch earlier in June of its Meta Video Joint Embedding Predictive Architecture 2 (V-JEPA 2), a powerful video-based world model that helps machines anticipate how the physical world behaves. Unlike language-only models, V-JEPA 2 learns from video data to predict object dynamics and human interactions using latent-space simulation. It allows robots to 'think before they act,' performing tasks like picking up and placing objects in unfamiliar environments. Ditch Big Tech and Buy These 3 Popular Stocks in 2025 Instead Dear Nvidia Stock Fans, Watch This Event Today Closely Can Broadcom Stock Hit $400 in 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Meta's bold move also includes new benchmarks to accelerate physical reasoning research, plus, a reported $14.3 billion investment in Scale AI, signaling CEO Mark Zuckerberg's intent to anchor AI deeply into Meta's ecosystem. But does this push into physical AI make META stock a buy, or should investors wait on the sidelines? Meta Platforms (META) has grown from a college social network into a global tech powerhouse, redefining how billions of people communicate. The California-based tech titan now oversees a sprawling digital empire, anchored by social media giants such as Instagram, WhatsApp, and Messenger, and is charging ahead into the future with ambitious bets in AI, augmented reality, and the metaverse. What began with a newsfeed has evolved into a full-scale push to shape how humans and machines interact in the next era of connectivity. That future-facing focus seems to be paying off. Meta's shares have surged more than 700% over the past decade. In 2025, META has so far delivered a standout 21% YTD gain, and over the past year, the stock has skyrocketed 38.8%, handily beating not just some of its tech peers, which flinched under pressure, but also the S&P 500 Index's ($SPX) returns. The surge was fueled by rising ad revenues, deeper AI integration, and investor faith in its metaverse roadmap. Meta's Q1 2025 earnings report, released on April 30, came out swinging, crushing expectations and fueling a 4.2% jump in the stock the very next day. Revenue climbed 16% year over year to $42.3 billion, beating Wall Street's estimate of $41.4 billion. But the real knockout punch came from EPS, soaring 37% to $6.43, 23.2% higher than forecasts. Meta's ad engine is still humming, with impressions up 5% and the average price per ad jumping 10%. User growth remains rock solid too, as, in March, daily active users across the company's app family reached 3.4 billion, up 6% year-over-year. Meta tightened the screws on costs and it paid off. Its operating income surged 27% to $17.56 billion, lifting margins to 41%. Plus, with $70.2 billion in cash and marketable securities and just $28.8 billion in long-term debt, Meta heads deeper into 2025 with a strong balance sheet and momentum on its side. CEO Mark Zuckerberg highlighted AI as the driving force behind the company's renewed energy, particularly Meta AI and its growing line of smart glasses. Meta AI has already hit nearly 1 billion monthly users. But the real story may be what's next. Looking ahead, management anticipates Q2 revenue to be between $42.5 billion and $45.5 billion, signaling continued strength. Plus, with capex now projected to be between $64 billion and $72 billion for 2025, Meta is going full throttle into AI infrastructure and next-gen computing. Analysts monitoring the social media company project its revenue for Q2 to be around $44.5 billion, and EPS for the quarter is anticipated to rise by 11.4% year over year to $5.75. Looking further ahead to fiscal 2025, the bottom line is expected to climb to $25.25 per share, up 5.8% annually. AI-driven robotics and autonomous systems are reshaping industries - from logistics to consumer tech - with speed and adaptability becoming the new gold standard. Meta's V-JEPA 2 steps into this evolving space as a potentially disruptive force. What truly elevates V-JEPA 2, however, is Meta's decision to open-source the framework. By releasing code, benchmarks, and training data, Meta is fostering a collaborative ecosystem, one that could fuel innovation far beyond its own walls. Yet this openness is a double-edged sword. It lowers barriers for startups but also gives its competitors access to refine their systems faster. For Meta, the model is a strategic leap, but long-term success depends on how well it is integrated, scaled, and monetized. Meta's ambition to dominate AI just got Wall Street's nod. Recently, Bank of America hiked its price target to $765, citing easing macroeconomic worries and expanding valuations. Buzz around Meta's roughly $14.3 billion Scale AI investment only adds fuel, signaling Zuckerberg's intent is to lead the AI race, not follow. Wall Street has got its foot on the gas for Meta. The stock holds a 'Strong Buy' consensus, signaling full-speed-ahead confidence in its trajectory. Of the 54 analysts offering recommendations, 45 are giving it a solid 'Strong Buy,' three advise a 'Moderate Buy,' four suggest a 'Hold,' and only two advocate a 'Strong Sell.' META's average analyst price target of $711,88 implies modest 2.4% potential upside. However, the Street-high price target of $935 suggests that the stock can still rally as much as 32% from here. On the date of publication, Sristi Suman Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Trending tickers: latest investor updates on Nike, Xiaomi, Cyngn, Spotify, Core Scientific and Unilever
Trending tickers: latest investor updates on Nike, Xiaomi, Cyngn, Spotify, Core Scientific and Unilever

Yahoo

time44 minutes ago

  • Yahoo

Trending tickers: latest investor updates on Nike, Xiaomi, Cyngn, Spotify, Core Scientific and Unilever

Nike (NKE) shares surged by almost 10% in after-hours trading, fuelled by growing investor optimism that the company's long-awaited turnaround strategy may finally take hold, even as it posted its worst quarterly earnings in over three years. On Thursday, the Oregon-based sportswear giant reported fourth-quarter revenues of $11.1bn (£8bn), surpassing analyst expectations, though it marked the lowest revenue figure since Q3 2022. Net income plummeted 86% to $211m, or 14 cents per share, compared to $1.5bn, or 99 cents per share, in the same period last year—yet still exceeded Wall Street forecasts. Nike's (NKE) chief executive Elliott Hill said: 'The results we're reporting today in Q4, and in FY 25 are not up to the Nike standard." The company also warned that US president Donald Trump's trade tariffs could cost it around an extra $1bn. Amid these results, Mamta Valechha, a consumer discretionary analyst at Quilter Cheviot, remained cautious. 'Nike (NKE) continues to slump, with its fourth quarter the worst in at least two decades. Sales were down 12%, while its operating margin was a meagre 2.9%. The sales themselves had actually come in ahead of really low expectations, producing an earnings beat.' Read more: FTSE 100 LIVE: Stocks higher as US and China sign trade agreement, US says 10 deals imminent Valechha pointed to underlying challenges, adding: 'These troubling numbers, though, suggest that Nike (NKE) may nearly be at rock bottom. The share price rallied strongly in after-market trading as investors are beginning to expect a positive rate of change going forward. It has been a difficult period for Nike following the pandemic, and the threat of tariffs simply is not helping the situation for the company.' Though the company's outlook for the coming quarter remains grim, Valechha noted that the road to recovery would likely be gradual. 'It will be a slow recovery, however. Management is expecting further sales declines and record-low operating margins for Q1. That said, it is setting itself a low bar, hoping to give itself room for manoeuvre and the ability to beat expectations from investors and begin to drive positive momentum back into the business.' Nike's (NKE) strategy to clean up inventory levels and reduce discounting could be pivotal in driving future growth. However, Valechha said that fresh, in-demand product launches are crucial. 'Ultimately, Nike needs to produce new products that people want to buy, bringing about increased demand to help bring sales back to the company. The green shoots of recovery are beginning to show themselves in some divisions, but more could soon be on the way.' Shares of Hong Kong-listed Xiaomi ( surged more than 5% to reach a record high on Friday before closing with 3.6% gains, following an overwhelming customer response to its new electric vehicle (EV). The consumer electronics giant, which has quickly expanded into the EV market, is now directly challenging Tesla (TSLA) with its latest offering, the YU7 electric luxury SUV. On Thursday, CEO Lei Jun revealed that the YU7's starting price would be 253,500 yuan ($35,322), undercutting Tesla's (TSLA) Model Y by 10,000 yuan. Tesla's Model Y starts at 263,500 yuan in China. Lei's announcement comes as part of Xiaomi's ( broader strategy to become a serious player in the electric vehicle sector, which has seen intense competition from industry leaders like Tesla. According to Xiaomi ( the YU7 received more than 200,000 orders within just three minutes of its official launch, a sign of the growing consumer appetite for EVs, especially those offering more affordable alternatives to established brands. Ahead of the vehicle's price revelation, analysts at Citi had forecasted that the YU7 would be priced between RMB 250,000-320,000 ($34,800 to $44,590), with expected monthly sales of around 30,000 units. Citi further predicted that as sales gain momentum, Xiaomi ( could reach annual sales figures of between 300,000 and 360,000 units. Cyngn (CYN) shares closed 1271% higher on Thursday and were 30% higher in pre-market trading, after the industrial automation company revealed a partnership with Nvidia (NVDA). The collaboration will see Cyngn's (CYN) vehicles, powered by Nvidia's (NVDA) Isaac robotics platform and the company's proprietary DriveMod software, change automation across industries such as logistics and manufacturing. The partnership is designed to enhance operational safety and efficiency within commercial operations. Cyngn's (CYN) announcement came ahead of its participation at Automatica 2025, a global robotics event where the company, along with several other robotics firms, will demonstrate Nvidia-powered technologies. Automatica is regarded as a prime stage for unveiling AI-driven systems in real-world industrial settings. The meteoric rise in Cyngn's (CYN) stock price marks a stark contrast to the company's recent struggles. Over the past 12 months, Cyngn had endured a near-total loss of its market value, driven by a series of setbacks that included delisting risks and disappointing earnings results over four consecutive quarters. However, the company has since regained Nasdaq (^IXIC) compliance in March 2025, paving the way for its dramatic comeback. Investors are now hoping that this partnership with Nvidia (NVDA) will mark the beginning of a sustained recovery for Cyngn (CYN). Spotify's (SPOT) shares were trading higher ahead of the US market open, following a 5% increase in the previous session, as analysts raised their price target in anticipation of the company's Q2 earnings report. Guggenheim Securities analyst Michael Morris reaffirmed his 'buy' rating on the stock and lifted his 12-month price target to $840 from $725. In a note to clients on Wednesday, Morris expressed confidence in Spotify's (SPOT) growth trajectory. 'Our conviction in the mid- and long-term growth opportunity at the global streaming audio leader remains intact,' he said. Morris highlighted several factors fuelling his optimism, including Spotify's (SPOT) 'core pricing power, potential tier expansion, expanded delivery of audio formats (led by audiobooks and podcasts), and the early-stage commerce opportunity presented by app-store changes". Read more: Why BP could still be a target as Shell quashes takeover rumours Spotify (SPOT) stock reached a milestone on Wednesday, achieving its third consecutive record high. The company is set to release its second-quarter 2025 results and shareholder presentation on Tuesday, 29 July, before the market opens. Core Scientific (CORZ) shares saw a significant boost ahead of the US market open, following a 35% rally on Thursday triggered by a Wall Street Journal report revealing that artificial intelligence infrastructure vendor CoreWeave (CRWV) is in talks to acquire the bitcoin (BTC-USD) mining and hosting provider. The stock was briefly halted after the news broke, then resumed trading with its second-largest rally since Core Scientific's (CORZ) return to the Nasdaq (^IXIC) in January 2024, following a successful reorganisation. The company's biggest one-day jump came in June 2024, when shares surged 40% after the announcement of a major AI business expansion with CoreWeave (CRWV). According to the Journal, citing sources familiar with the situation, a potential transaction could be finalised in the coming weeks, pending any unforeseen obstacles. The deal would deepen an existing partnership between the two companies, which already includes billions of dollars in contracted commitments. With Thursday's surge, Core Scientific (CORZ) now has a market capitalisation of nearly $5bn, approximately five times the valuation implied by CoreWeave's (CRWV) previously rejected takeover bid from last year. Meanwhile, CoreWeave's stock fell by about 1% on Thursday. Unilever (ULVR.L) is paying $1.5bn to acquire US-based personal care brand Dr Squatch, according to the Financial Times. The FTSE 100-listed (^FTSE) company announced the acquisition on Monday, purchasing Dr Squatch from private equity firm Summit Partners for an undisclosed sum, though sources familiar with the transaction have confirmed the $1.5bn price tag. The deal signals the consumer goods giant's continued focus on upmarket, higher-growth sectors, despite its previous setbacks with razor subscription service Dollar Shave Club. Dr Squatch, known for its "natural" soaps, deodorants, shampoos, and other personal care products, has carved out a niche in the competitive male grooming market. The brand has built momentum through viral marketing campaigns and celebrity endorsements, including an ad with Hollywood actress Sydney Sweeney in a bubble bath and another with boxing legend Mike Tyson taking an ice bath. The brand's products are sold directly to consumers through its website and through third-party retailers, helping it establish a direct-to-consumer business model that has been integral to its rapid growth. For Unilever (ULVR.L), the acquisition marks an effort to recalibrate its portfolio by investing in categories with higher growth potential, particularly in the premium and natural personal care segments. This follows a series of strategic acquisitions aimed at bolstering its position in the fast-growing male grooming in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store